Review of cannabinoid treatments for autism spectrum disorder symptoms

Uncontrolled case series documented improvements in both core ASD symptoms and behavioral challenges with CBD-rich cannabis extracts. However, placebo-controlled studies of CBD-rich extracts and pure CBD showed mixed efficacy results. Studies demonstrated relatively high safety and tolerability.

Mini-review summarizing existing literature and ongoing clinical trials of cannabinoid treatments for ASD, including uncontrolled case series and placebo-controlled studies of CBD-rich extracts and pure CBD.

ASD affects approximately 3% of school-age children with no approved treatment for core symptoms. Current medications (risperidone, aripiprazole) only address irritability with limited effectiveness and common side effects. Families increasingly seek cannabinoid alternatives.

The gap between parental enthusiasm for CBD in ASD and the mixed clinical evidence mirrors patterns seen with other conditions where traditional treatments fall short. The relatively good safety profile may justify continued investigation even without proven efficacy.

Uncontrolled studies are susceptible to placebo and expectancy effects, particularly in behavioral conditions. Placebo-controlled trials are few and showed mixed results. Different formulations (pure CBD vs. CBD-rich extracts) may have different effects.